Johnson & Johnson announced the U.S. FDA approved DARZALEX FASPRO as a single agent treatment for adult patients with high-risk smoldering multiple myeloma. DARZALEX FASPRO is the first and only approved treatment for HR-SMM, enabling earlier intervention before the disease progresses to active multiple myeloma.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- FDA approves J&J’s Darzalex Faspro for high-risk smoldering multiple myeloma
- FDA awards second batch of National Priority Vouchers
- Johnson & Johnson announces FDA approval of Caplyta
- Zimmer Biomet price target lowered to $112 from $122 at BTIG
- M&A: Diaper Group Kimberly-Clark Leaks 15% After $48.7B Purchase of Tylenol Maker Kenvue